セルベースアッセイ市場：提供製品、用途、エンドユーザー別-2025-2030年の世界予測

セルベースアッセイ市場は、2023年に206億4,000万米ドルと評価され、2024年には222億8,000万米ドルに達すると予測され、CAGR 8.11％で成長し、2030年には356億5,000万米ドルに達すると予測されています。

セルベースアッセイは、創薬や薬剤開発において主に利用される極めて重要なツールであり、細胞メカニズムや生物学的に活性な化合物の相互作用に関する重要な知見を提供します。これらのアッセイは、生理学的な観点から新薬化合物の有効性や毒性を試験するために不可欠であり、製薬・バイオテクノロジー分野に大きく貢献しています。その用途は、ハイスループット・スクリーニング、自動化されたハンドリング、細胞生存率、増殖、細胞毒性、シグナル伝達を含む様々な生物学的プロセスの試験など多岐にわたる。最終用途は、製薬会社、学術機関、研究所、バイオテクノロジー企業で、これらのアッセイを活用して医薬品開発パイプラインを合理化しています。

細胞ベースのアッセイ市場は、精密医療に対する需要の増加、自動化の進展、包括的なデータ分析を提供する高度なイメージングと分析ツールの統合によって、力強い成長を遂げています。生物製剤と個別化医療の台頭は、これらのアッセイの有用性をさらに拡大しています。特筆すべきは、業界の主要企業間の戦略的提携やパートナーシップが極めて重要な成長要因であり、イノベーションと市場拡大を促進していることです。しかし、高度なアッセイキットの高コストや厳しい規制の枠組みといった課題が大きな障害となり、市場の拡大を抑制する可能性があります。

3D細胞培養や臓器オンチップモデルの開発には目覚ましい機会が存在し、洗練された生理学的に適切なin vitro検査システムの次のフロンティアとなります。アッセイ感度の向上は、データ処理のための人工知能（AI）や機械学習（ML）の統合と相まって、革新のための画期的な道を提示します。こうした機会を活用するため、企業はアッセイ技術を改良するための研究開発に投資し、技術共有と市場浸透のための戦略的提携を追求すべきです。有望な見通しとは裏腹に、市場関係者は成長を維持するために、コスト抑制や規制遵守を含む経営上の課題を克服しなければならないです。これらの戦略に注力することで、企業はセルベースアッセイ市場の大きな可能性を活用し、将来の生物医学研究のリーダーとしての地位を確立することができます。

市場力学：急速に進化するセルベースアッセイ市場の主要市場インサイトを公開

セルベースアッセイ市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の開発と創薬・開発活動の拡大
  • 世界の研究活動の拡大と医薬品研究への資金援助
  • 個別化医療の普及とカスタマイズされたセルベースアッセイの需要
• 市場抑制要因
  • セルベースアッセイの使用における複雑さと熟練者の不足
• 市場機会
  • セルベースアッセイの精度、効率、性能を向上させるための継続的な技術革新
  • 特定の疾患を検出する診断ツールとしてのセルベースアッセイの採用
• 市場の課題
  • セルベースアッセイの性能限界と技術的制約

ポーターのファイブフォース：セルベースアッセイ市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：セルベースアッセイ市場における外部からの影響の把握

外部マクロ環境要因は、セルベースアッセイ市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析セルベースアッセイ市場における競合情勢の把握

セルベースアッセイ市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスセルベースアッセイ市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、セルベースアッセイ市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨セルベースアッセイ市場における成功への道筋を描く

セルベースアッセイ市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加と医薬品の発見・開発活動の拡大
    • 世界中の調査活動への重点拡大と医薬品調査への資金提供
    • 個別化医療の普及とカスタマイズされた細胞ベースのアッセイの需要
  • 抑制要因
    • 細胞ベースのアッセイの使用の複雑さと熟練した人材の不足
  • 機会
    • 細胞ベースのアッセイの精度、効率、パフォーマンスを向上させるための継続的なイノベーション
    • 特定の疾患を検出するための診断ツールとしての細胞ベースのアッセイの採用
  • 課題
    • 細胞ベースのアッセイのパフォーマンスの限界と技術的制約
• 市場セグメンテーション分析
  • 提供内容：細胞ベースのアッセイの実施に不可欠な役割を果たす細胞ベースのアッセイの消耗品の革新を拡大
  • エンドユーザー：製薬会社やバイオテクノロジー会社による医薬品開発プロセスにおける細胞ベースのアッセイの広範な活用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 セルベースアッセイ市場オファリング

• 消耗品
  • アッセイキット
  • 細胞株
  • マイクロプレート
  • プローブとラベル
  • 試薬
• 機器
• サービス

第7章 セルベースアッセイ市場：用途別

• 基礎調査
• 創薬
  • 薬力学研究
  • 薬物動態研究
  • 毒性研究

第8章 セルベースアッセイ市場：エンドユーザー別

• 学術機関および政府機関
• 契約調査機関
• 製薬・バイオテクノロジー企業

第9章 南北アメリカのセルベースアッセイ市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のセルベースアッセイ市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのセルベースアッセイ市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ARRALYZEは、機能アッセイのリアルタイムモニタリングのための完全自律型単一細胞プラットフォームCellShepherdを発売しました。
  • InSphero、ATCCと共同で先進的な3D細胞ベースアッセイにより腫瘍学調査に革命を起こす
  • ベックマン・コールター・ライフサイエンスと10x Genomicsが提携
• 戦略分析と提言

企業一覧

• Abnova Corporation
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Canvax Reagents S.L.
• Cell Biolabs, Inc.
• Cell Signaling Technology, Inc.
• Charles River Laboratories, Inc.
• Corning Inc.
• Danaher Corporation
• Elabscience Bionovation Inc.
• Enzo Life Sciences, Inc.,
• Eurofins Scientific SE
• GE HealthCare Technologies Inc.
• InSphero AG
• Intertek Group plc
• InvivoGen
• Lonza Group Ltd.
• Merck KGaA
• Molecular Devices, LLC.
• Perkinelmer, Inc.
• Promega Corporation
• ReadyCell, S.L.
• Sartorius AG
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. CELL-BASED ASSAY MARKET RESEARCH PROCESS
• FIGURE 2. CELL-BASED ASSAY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CELL-BASED ASSAY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CELL-BASED ASSAY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CELL-BASED ASSAY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CELL-BASED ASSAY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CELL-BASED ASSAY MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CELL-BASED ASSAY MARKET DYNAMICS
• TABLE 7. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY CELL LINES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY MICROPLATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY PROBES & LABELS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY PHARMACODYNAMIC STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY PHARMACOKINETIC STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY TOXICITY STUDIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY ACADEMIC & GOVERNMENT INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CELL-BASED ASSAY MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. CANADA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 45. CANADA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 46. CANADA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 48. CANADA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES CELL-BASED ASSAY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. CHINA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 72. CHINA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 73. CHINA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 75. CHINA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. INDIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 77. INDIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 78. INDIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 80. INDIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA CELL-BASED ASSAY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. ITALY CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 163. ITALY CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 164. ITALY CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 166. ITALY CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. POLAND CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 183. POLAND CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 184. POLAND CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 186. POLAND CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. QATAR CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 188. QATAR CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 189. QATAR CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 191. QATAR CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM CELL-BASED ASSAY MARKET SIZE, BY OFFERINGS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM CELL-BASED ASSAY MARKET SIZE, BY CONSUMABLES, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM CELL-BASED ASSAY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM CELL-BASED ASSAY MARKET SIZE, BY DRUG DISCOVERY, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM CELL-BASED ASSAY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. CELL-BASED ASSAY MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 238. CELL-BASED ASSAY MARKET, FPNV POSITIONING MATRIX, 2023

The Cell-based Assay Market was valued at USD 20.64 billion in 2023, expected to reach USD 22.28 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 35.65 billion by 2030.

Cell-based assays are pivotal tools utilized predominantly in drug discovery and development, providing critical insights into cellular mechanisms and the interactions of biologically active compounds. These assays are essential for testing the efficacy and toxicity of new drug compounds in a physiological context, significantly contributing to the pharmaceutical and biotechnology sectors. Their application extends across high-throughput screening, automated handling, and the testing of various biological processes, including cell viability, proliferation, cytotoxicity, and signal transduction. The end-use spectrum covers pharmaceutical companies, academic institutes, research labs, and biotechnology firms, which leverage these assays to streamline the drug development pipeline.

The market for cell-based assays is experiencing robust growth, driven by increasing demand for precision medicine, advancements in automation, and the integration of advanced imaging and analytical tools that offer comprehensive data analysis. The rise of biologics and personalized medicine has further expanded the utility of these assays. Notably, strategic collaborations and partnerships among key players in the industry are pivotal growth factors, fostering innovation and market expansion. However, challenges such as high costs of advanced assay kits and stringent regulatory frameworks pose significant obstacles, potentially restraining market progression.

Remarkable opportunities exist in the development of 3D cell cultures and organ-on-chip models, representing the next frontier of sophisticated and physiologically relevant in vitro testing systems. Enhanced assay sensitivity, coupled with artificial intelligence (AI) and machine learning (ML) integration for data processing, presents a ground-breaking avenue for innovation. To capitalize on these opportunities, businesses should invest in R&D to refine assay technologies and pursue strategic alliances for technology sharing and market penetration. Despite the promising outlook, market players must navigate operational challenges, including cost containment and regulatory compliance, to sustain growth. By focusing on these strategies, companies can harness the extensive potential within the cell-based assays market, positioning themselves as leaders in the future of biomedical research.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell-based Assay Market

The Cell-based Assay Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases and growing drug discovery and development activities
  • Expanding focus on research activities across the world and funding for pharmaceutical research
  • Proliferation of personalized medicine and the demand for customized cell-based assays
• Market Restraints
  • Complexities in the usage of cell-based assays and lack of skilled personnel
• Market Opportunities
  • Ongoing innovations to improve the accuracy, efficiency, and performance of cell-based assays
  • Adoption of cell-based assays as a diagnostic tool for detecting certain diseases
• Market Challenges
  • Performance limitations and technical constraints of cell-based assays

Porter's Five Forces: A Strategic Tool for Navigating the Cell-based Assay Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell-based Assay Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell-based Assay Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell-based Assay Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell-based Assay Market

A detailed market share analysis in the Cell-based Assay Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell-based Assay Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell-based Assay Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell-based Assay Market

A strategic analysis of the Cell-based Assay Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell-based Assay Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Canvax Reagents S.L., Cell Biolabs, Inc., Cell Signaling Technology, Inc., Charles River Laboratories, Inc., Corning Inc., Danaher Corporation, Elabscience Bionovation Inc., Enzo Life Sciences, Inc.,, Eurofins Scientific SE, GE HealthCare Technologies Inc., InSphero AG, Intertek Group plc, InvivoGen, Lonza Group Ltd., Merck KGaA, Molecular Devices, LLC., Perkinelmer, Inc., Promega Corporation, ReadyCell, S.L., Sartorius AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cell-based Assay Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offerings, market is studied across Consumables, Instruments, and Services. The Consumables is further studied across Assay Kits, Cell Lines, Microplates, Probes & Labels, and Reagents.
• Based on Application, market is studied across Basic Research and Drug Discovery. The Drug Discovery is further studied across Pharmacodynamic Studies, Pharmacokinetic Studies, and Toxicity Studies.
• Based on End-User, market is studied across Academic & Government Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases and growing drug discovery and development activities
    • 5.1.1.2. Expanding focus on research activities across the world and funding for pharmaceutical research
    • 5.1.1.3. Proliferation of personalized medicine and the demand for customized cell-based assays
  • 5.1.2. Restraints
    • 5.1.2.1. Complexities in the usage of cell-based assays and lack of skilled personnel
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing innovations to improve the accuracy, efficiency, and performance of cell-based assays
    • 5.1.3.2. Adoption of cell-based assays as a diagnostic tool for detecting certain diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Performance limitations and technical constraints of cell-based assays
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offerings: Expanding innovations in consumables of cell-based assays owing to their essential role in the execution of assays
  • 5.2.2. End-User: Extensive utilization of cell-based assays by pharmaceutical and biotechnology companies for drug development process
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Cell-based Assay Market, by Offerings

• 6.1. Introduction
• 6.2. Consumables
  • 6.2.1. Assay Kits
  • 6.2.2. Cell Lines
  • 6.2.3. Microplates
  • 6.2.4. Probes & Labels
  • 6.2.5. Reagents
• 6.3. Instruments
• 6.4. Services

7. Cell-based Assay Market, by Application

• 7.1. Introduction
• 7.2. Basic Research
• 7.3. Drug Discovery
  • 7.3.1. Pharmacodynamic Studies
  • 7.3.2. Pharmacokinetic Studies
  • 7.3.3. Toxicity Studies

8. Cell-based Assay Market, by End-User

• 8.1. Introduction
• 8.2. Academic & Government Institutes
• 8.3. Contract Research Organizations
• 8.4. Pharmaceutical & Biotechnology Companies

9. Americas Cell-based Assay Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Cell-based Assay Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Cell-based Assay Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ARRALYZE launches CellShepherd, a fully autonomous single-cell platform for real-time monitoring of functional assays
  • 12.3.2. InSphero To Revolutionize Oncology Research Through Advanced 3D Cell-Based Assays With ATCC
  • 12.3.3. Beckman Coulter Life Sciences and 10x Genomics Partner
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abnova Corporation
• 2. Agilent Technologies, Inc.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. Canvax Reagents S.L.
• 6. Cell Biolabs, Inc.
• 7. Cell Signaling Technology, Inc.
• 8. Charles River Laboratories, Inc.
• 9. Corning Inc.
• 10. Danaher Corporation
• 11. Elabscience Bionovation Inc.
• 12. Enzo Life Sciences, Inc.,
• 13. Eurofins Scientific SE
• 14. GE HealthCare Technologies Inc.
• 15. InSphero AG
• 16. Intertek Group plc
• 17. InvivoGen
• 18. Lonza Group Ltd.
• 19. Merck KGaA
• 20. Molecular Devices, LLC.
• 21. Perkinelmer, Inc.
• 22. Promega Corporation
• 23. ReadyCell, S.L.
• 24. Sartorius AG
• 25. Thermo Fisher Scientific Inc.